High MVP Expression Predicts Poor Survival in Oral Squamous Cell Carcinoma

Share this content:

the Cancer Therapy Advisor take:

Surgery or radiotherapy are common local treatments for oral carcinoma. Due to advances in therapy, long-term survival for patients is increasing, but local advanced cases have poorer outcomes. Vaults, which comprise ribonucleoprotein particles with the proteins MVP, ADP-ribose, VPARP, and TEP1 as well as small untranslated RNA, are linked to treatment resistance. MVP, the major vault protein, inhibits the COP-1/p53 axis, which hinders apoptosis and leads to resistance to radiotherapy. DNA-damaging agents cause MVP to overexpress. According to a study published in Radiation Oncology, researchers found that high MVP expression is a prognostic indicator for oral squamous cell carcinoma. Pedro C. Lara and colleagues analyzed the MVP expression for 131 patients with oral squamous cell carcinoma between July 1989 and April 2005. Patients with stage I-II tumors received surgery while patients with stage III-IV tumors received postoperative radiotherapy. 123.11 months was the average follow-up for survivors. Through immunohistochemistry in paraffin-embedded tumor tissue, results found that 85.5 percent of the patients had positive MVP expression, which was associated with insulin-like growth factor receptor-1 (IGF—1R) expression. While tumor stage was the top prognostic factor, overexpression of MVP and IGF-1R indicated poor disease-free survival and cause-specific survival for patients with stage III-IV tumors.

Testing of Oral Cancer Detection Tool Underway
High MVP Expression Predicts Poor Survival in Oral Squamous Cell Carcinoma
This study was carried out to explore the clinical association between MVP expression and prognosis on a series of OCSCC patients treated by surgery and radiotherapy. MVP may have a role in favouring increased genetic instability by reducing DNA damage repair by means of non-homologous end joining (NHEJ) and downregulating Ku70/80 expression.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs